Table 2.
SLE (n = 6159) | Non-SLE (n = 18,477) | Adjusted HR (95% CI) | P-value | |||||
---|---|---|---|---|---|---|---|---|
Type 2 diabetes n (%) | PYs | Rate* | Type 2 diabetes n (%) | PYs | Rate* | |||
Overall analysis | 206 (3.34) | 15814.33 | 130.26 | 507 (2.74) | 50,108.93 | 101.18 | 1.22 (1.04–1.44) | .0179 |
Stratified analysis | ||||||||
Age (yr) | ||||||||
20–34 | 42 (1.43) | 7805.24 | 53.81 | 100 (1.13) | 24,268.34 | 41.21 | 1.23 (0.85–1.78) | .2672 |
35–49 | 71 (3.52) | 5210.63 | 136.26 | 155 (2.56) | 16,491.81 | 93.99 | 1.29 (0.97–1.72) | .0817 |
50–64 | 53 (6.62) | 1966.01 | 269.58 | 144 (5.99) | 6324.26 | 227.69 | 1.05 (0.76–1.45) | .7887 |
≥65 | 40 (9.88) | 832.45 | 480.51 | 108 (8.89) | 3024.52 | 357.08 | 1.20 (0.83–1.74) | .3374 |
Gender | ||||||||
Female | 168 (3.10) | 14022.09 | 119.81 | 419 (2.58) | 44,128.54 | 94.95 | 1.21 (1.01–1.45) | .0425 |
Male | 38 (5.10) | 1792.24 | 212.03 | 88 (3.94) | 5980.39 | 147.15 | 1.32 (0.89–1.96) | .1623 |
Monthly income (NTD) | ||||||||
<20,000 | 130 (3.54) | 9448.11 | 137.59 | 281 (2.69) | 28,717.17 | 97.85 | 1.36 (1.10–1.69) | .0041 |
20,000–40,000 | 57 (3.03) | 4773.42 | 119.41 | 170 (2.90) | 15,592.44 | 109.03 | 1.00 (0.74–1.35) | .9822 |
>40,000 | 19 (3.14) | 1592.80 | 119.29 | 56 (2.59) | 5799.32 | 96.56 | 1.18 (0.70–2.01) | .5339 |
Comorbidity | ||||||||
Hypertension | 59 (8.93) | 1501.91 | 392.83 | 103 (10.26) | 2514.65 | 409.60 | 1.09 (0.78–1.52) | .6025 |
Hyperlipidemia | 15 (7.81) | 431.87 | 347.33 | 32 (10.32) | 775.62 | 412.57 | 1.03 (0.54–1.97) | .9228 |
Coronary artery disease | 14 (8.64) | 338.76 | 413.27 | 23 (10.27) | 557.07 | 412.87 | 1.04 (0.52–2.09) | .9126 |
Cerebrovascular accident | 19 (10.80) | 358.18 | 530.47 | 15 (10.87) | 334.11 | 448.95 | 1.79 (0.86–3.73) | .1209 |
Chronic renal disease | 6 (6.38) | 180.16 | 333.04 | 4 (10.53) | 83.04 | 481.67 | 0.62 (0.14–2.87) | .5421 |
CI = confidence interval, HR = hazard ratio, NTD = New Taiwan Dollar, PYs = person-years, SLE = systemic lupus erythematosus.
Per 10,000 person-years.